Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Link
http://www.nature.com/articles/onc2013206.pdf
Reference158 articles.
1. Huggins C . Prostatic cancer treated by orchiectomy; the five year results. J Am Med Assoc 1946; 131: 576–581.
2. Harris WP, Mostaghel EA, Nelson PS, Montgomery B . Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6: 76–85.
3. Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G . Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One 2010; 5: e13500.
4. Dayyani F, Gallick GE, Logothetis CJ, Corn PG . Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011; 103: 1665–1675.
5. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone GH et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089–3094.
Cited by 592 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation;Journal of Medical Economics;2024-02-02
2. Targeting prostate tumor low–molecular weight tyrosine phosphatase for oxidation-sensitizing therapy;Science Advances;2024-02-02
3. Evaluation of AR, AR-V7, and p160 family as biomarkers for prostate cancer: insights into the clinical significance and disease progression;Journal of Cancer Research and Clinical Oncology;2024-02-02
4. Prostate Cancer Liver Metastasis: An Ominous Metastatic Site in Need of Distinct Management Strategies;Journal of Clinical Medicine;2024-01-27
5. Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice;Frontiers in Oncology;2024-01-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3